Article

Miravant results revived: Bausch & Lomb to review potential AMD drug

Santa Barbara, CA-Bausch & Lomb will review results of Miravant Medical Technologies' SnET2 trials with an option to negotiate the exclusive worldwide license to develop and commercialize the drug for the treatment of wet age-related macular degeneration (AMD).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.